Agnuside
Based on 1 publication(s) in Google Scholar
Agnuside is used in the study of asthma, inflammation, and angiogenic diseases. Agnuside is an orally active compound that can be extracted from Vitex negundo.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.90%
- No. CAS: 11027-63-7
- Fòrmula: C22H26O11
- Peso molecular:466.44
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Reprogramming Compound Library
HY-L039
-
Glycoside Compound Library
HY-L042
-
Oxygen Sensing Compound Library
HY-L045
-
Terpenoids Library
HY-L056
-
Phenols Library
HY-L057
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Food-Sourced Compound Library
HY-L094
-
Anti-Cancer Natural Product Library
HY-L107
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Cancer Stem Cells Compound Library
HY-L135
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Membrane Protein-targeted Compound Library
HY-L149
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Tibetan Medicine Compound Library
HY-L191
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
RNA Binding Bioactive Compound Library
HY-L248
-
Mass Spectrometry Natural Product Library
HY-L262
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Apoptosis Compound Library
HY-L003
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
Publications Citing Use of MedChemExpress (MCE) Agnuside
MoreVer todos los productos específicos de isoformas Caspase
More
Actividad biológica
|
EP |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HUVEC | EC50 |
1.376 μg/mL
Compound: Agnuside
|
Pro-angiogenic activity in HUVEC assessed as increase in cell proliferation after 96 hrs by DAPI staining-based spectrofluorometric analysis
Pro-angiogenic activity in HUVEC assessed as increase in cell proliferation after 96 hrs by DAPI staining-based spectrofluorometric analysis
|
[PMID: 30340142] |
Agnuside (100 μM, 12-20 h) decreases the expression of iNOS, COX-2 and IL-8 proteins, and has anti-inflammatory effect in RAW264.7 and HT-29 cells stimulated by LPS (1 μg/mL/100 ng/mL) [2].
Agnuside (0.1-2500 ng/mL, 20-96 h) promotes angiogenesis in HUVEC by promoting cell proliferation (EC50= 1.376 µg/mL) in a time- and dose-dependent manner[3].
Agnuside (3 μM, 4 h) significantly reduces the levels of caspase-1, ASC, NLRP3, HIF-1α, IL-1β and IL-18 to inhibit inflammation in LPS (10 μg/ml) -stimulated fibroblast-like synoviocytes (FLSs)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/C female mice model [1]
-
Dosage:30 mg/kg, 60 mg/kg
-
Administration:Oral gavage (p.o.); Single dose;
-
Result:Decreased the expression of LC3B and increased the expression of Beclin1/p62 (LC3B and Beclin1/p62 are autophagy markers).
Decreased the levels of IgE and IL-4/ IL-10 in a dose-dependent manner.( IgE and IL-4/ IL-10 are allergic inflammatory mediators)
-
Animal Model:KAO rat model[4]
-
Dosage:6.25 mg Monosodium iodoacetate (MIA): 1 mg
-
Administration:Oral gavage (p.o.); Single dose
-
Result:Alleviated the degree of local hypoxia in the synovial tissue of rats and significantly reduced the level of pro-fibrotic substances in the synovial tissue.
Inhibited the accumulation of HIF-1α and activation of NLRP3 inflammasome.
Chemical Information
-
No. CAS 11027-63-7
-
Appearance Solid
-
Peso molecular 466.44
-
Fòrmula C22H26O11
-
Color White to yellow
-
SMILES
OC[C@H]([C@@H](O)[C@H](O)[C@H]1O)O[C@@]1([H])O[C@H]2[C@@]3([H])[C@](C=CO2)([H])[C@H](O)C=C3COC(C4=CC=C(O)C=C4)=O
-
Synonyms
Agnoside
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
ESRRA-ATG5-Mediated mitophagy enhances arginine metabolism to alleviate diabetic kidney disease. [Abstract]2025 Dec 23:1-25. PMID: 41376268
Solvente y solubilidad
DMSO : 100 mg/mL (214.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Tirpude NV, et al. Agnuside mitigates OVA-LPS induced perturbed lung homeostasis via modulating inflammatory, autophagy, apoptosis-fibrosis response and myeloid lineages in mice model of allergic asthma. Int Immunopharmacol. 2022 May;106:108579. [Content Brief]
[2]. Le DD, et al. Iridoid derivatives from Vitex rotundifolia L. f. with their anti-inflammatory activity. Phytochemistry. 2023 Jun;210:113649. [Content Brief]
[3]. Pillarisetti P, Myers KA. Identification and characterization of agnuside, a natural proangiogenic small molecule. Eur J Med Chem. 2018 Dec 5;160:193-206. [Content Brief]
[4]. Zhang L, et al. Agnuside Alleviates Synovitis and Fibrosis in Knee Osteoarthritis through the Inhibition of HIF-1α and NLRP3 Inflammasome. Mediators Inflamm. 2021 Mar 16;2021:5534614. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1439 mL | 10.7195 mL | 21.4390 mL | 53.5975 mL |
| 5 mM | 0.4288 mL | 2.1439 mL | 4.2878 mL | 10.7195 mL | |
| 10 mM | 0.2144 mL | 1.0719 mL | 2.1439 mL | 5.3597 mL | |
| 15 mM | 0.1429 mL | 0.7146 mL | 1.4293 mL | 3.5732 mL | |
| 20 mM | 0.1072 mL | 0.5360 mL | 1.0719 mL | 2.6799 mL | |
| 25 mM | 0.0858 mL | 0.4288 mL | 0.8576 mL | 2.1439 mL | |
| 30 mM | 0.0715 mL | 0.3573 mL | 0.7146 mL | 1.7866 mL | |
| 40 mM | 0.0536 mL | 0.2680 mL | 0.5360 mL | 1.3399 mL | |
| 50 mM | 0.0429 mL | 0.2144 mL | 0.4288 mL | 1.0719 mL | |
| 60 mM | 0.0357 mL | 0.1787 mL | 0.3573 mL | 0.8933 mL | |
| 80 mM | 0.0268 mL | 0.1340 mL | 0.2680 mL | 0.6700 mL | |
| 100 mM | 0.0214 mL | 0.1072 mL | 0.2144 mL | 0.5360 mL |
Agnuside Related Classifications
HY-N2518 Related Classifications
Powered by Bioz